Considering that the knockdown of BRCA1 caused reduction of the FADD level, we suggest that the loss of BRCA1 (or its inactivation) in a tumor can cause reduced levels of FADD that in turn desensitizes cells to a FasL-mediated anti-proliferative effect. This evidence concerns the gene BRCA1 and neoplasm.